Grow Therapy vs Hims & Hers

Side-by-side comparison of AI visibility scores, market position, and capabilities

Hims & Hers leads in AI visibility (86 vs 72)
Grow Therapy logo

Grow Therapy

LeaderDigital Health

Mental Health Marketplace

Raised $150M Series D (Mar 2026) led by TCV and Goldman Sachs Alternatives. $1B+ annualized revenue. 7M visits in 2025. 26K providers, 220M covered lives.

AI VisibilityBeta
Overall Score
B72
Category Rank
#103 of 596
AI Consensus
86%
Trend
stable
Per Platform
ChatGPT
70
Perplexity
70
Gemini
72

About

Grow Therapy is the largest insurance-covered mental health provider marketplace in the US, connecting 26,000 therapists and psychiatrists with patients across 220 million covered lives. The company raised $150 million in Series D financing in March 2026 led by TCV and Goldman Sachs Alternatives after crossing $1 billion in annualized revenue — rare proof of genuine unit economics in behavioral health, which has historically struggled to achieve profitability at scale.

Full profile
Hims & Hers logo

Hims & Hers

EmergingHealthcare

Telehealth Pharmacy

Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.

AI VisibilityBeta
Overall Score
A86
Category Rank
#8 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
92
Gemini
83

About

Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.

Full profile

AI Visibility Head-to-Head

72
Overall Score
86
#103
Category Rank
#8
86
AI Consensus
79
stable
Trend
stable
70
ChatGPT
88
70
Perplexity
92
72
Gemini
83
68
Claude
90
74
Grok
89

Key Details

Category
Mental Health Marketplace
Telehealth Pharmacy
Tier
Leader
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Grow Therapy
Mental Health Marketplace
Only Hims & Hers
Telehealth Pharmacy

Integrations

Only Grow Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.